Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
eNq1mF1v2jAUhu/5FVHuSYCOj06BamPthtSqjBZt2k1lkgOYBTs9tvnYr59DqAaTo7YGX8Z23nPi8/rxUaKrzTL1VoCCctb160HN94DFPKFs1vXHjzfVjn/Vq0QLsiIHy9pBLag3fC9OiRBdP58NJkCYCH7e3X4B/T6g36t4EZ8sIJZH65SkafCNiPkdyfI1XrTiNPGWIOc86fqZkrtRLxISdRa9NcffIiMxROF+5HB28fThcDwKc7E3qCoBeEvYzCgKzEozVojAZJ9ImHHcluR7YaVNxQgEVxjDkMj5EPmKJpAYQ0xJKsAqyHSdPACuUpB5EKN4uIiXwkqcLMhmBM8Dc9Kf9GxfbmS1Vq23m61Wu1XvXLRbl1ah8GCrzFXQHxHGTx0d57IRAgtJrF25tdw2KoYcJUkdVYWK/rGxHMVBeH61+gkVWUq2wUJktltFkOhpQH383X1I/gWPqIGU6j37T5+pNA3fmfV4jwtHGec06nPFZAk1bka2G9HnTMKmvKJ2oJObvRcpiPPJ/uHMDPmhmqQ0tkWaho4CIcejQTnRzgmDz0TAGN3R4AdlCV+L81PmsKqOss92oDSKZpjUnxqXnVa92bQ+RL+0hUpumGuFPINQ84eKU7AyYFN+KlC0K81SL548mx13fQ6PSQolnU7Vki3ahy+NmTOnuztFxYRR9Ov1o609vivA7cPu0ShNk+5LYe246wLm2ouleb/f2cUBd9ICKzSDYy5lJj6G4ZyIqiB6h4Ipnh3qB/eou+bbyWVdNC8FGB2lPiluvLdXx/aAvXaVn9qe7t/ft8HGGBIVnFCHgsXOiDm4Pj+E//WmztIeHlHDXZhdH0kk5cxVf6MmRsWTsK/Lym5Qs+F+OqUl/0FKbRmFxT+YXiUK8/8vvcpf0bLidA==
URVBWC5FhDB9V6bE
Listen
